Kodak cautions users of the Ektachem single-slide creatinine method (1) (EKTA/CREA) that high concentrations of creatine in serum may lead to a "Substrate Depletion" flag during the analysis (2). The procedure recommended by Kodak to circumvent this flag is dilution of the specimen and re-analysis. We have encountered this phenomenon on several occasions and herein document these occurrences in two patients.
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Case A: This 60-year-old man with a history of angina was admitted to the hospital in cardiac arrest. He was found to have an embolic occlusion and thrombosis in the arterial supply to the right lower extremity for which a thrombectomy and a femoral-popliteal bypass were performed. He developed rhabdomyolysis and acute renal failure with anuria that was treated with hemodialysis. The initial EKTAJCREA analysis (Ektachem 700#{174}; Eastman KOdak Co., Rochester, NY 14650) was rejected with a printout of "Out of Range" and "Substrate Depleted". After dilution of the specimen, the creatinine resultwas 87 mg/L (reference limits 7-17 mg/L) and the serum creatine was 69 mgfL 
Case B:
This 26-year-old man had a history of intravenous drug abuse and chronic renal failure due to membranoproliferative glomerulonephritis. He was admitted with severe ascites. Lab. studies indicated anemia, marked hypoalbuminemia, and antibodies to human immunodeficiency virus (H1V). The initial serum creatinine by EKTA/CREA was rejected as in Case A; however, after dilution of the specimen, a result of 27 mgfL was obtained. The patient's serum creatine concentration at this time was 136 mgfL. After four days the creatine concentration had declined to 52 mgfL, a concentration that allowed direct measurement of creatinine on the Ektachem 700 (see Figure 1) .
Experimental.
To better understand concentration relationships between creatine, creatinine, and final creatinine results, we added various concentrations of creatinine and creatine to our "normal" human serum pool (3), then assayed each sample with the Ektachem 700, using EKTA/ CREA (generation 1) slides. Any sample rejected as "Out of Range" by the Ektachem was diluted twofold with a 70 g/L solution of bovine albumin in isotonic saline and re-ana- limit for creatine, i.e., for men 4 mgfL, and for women 7 mg/ L. As expected, samples with a higher creatinine concentration require less creatine for this interference to be manifested.
Evidently creatine interference has no substantive impact on the clinical utility of the Kodak Ektachem single-slide method, because any flagged value is automatically diluted as a part of the routine protocol. Indeed, a "Substrate Depletion" flag should alert one of a possible creatine abnormality and the associated clinical implications, e.g., rhabdomyolysis or other disorders involving destruction or wasting of muscle mass and associated renal failure. The role of interleukin 2 (1L2) in immune regulation has been much investigated (1). Theoretically, this lymphokine should have a direct or indirect key role in immune deficiencies in many patients with lymphoproliferative diseases.
An Interleukln 2 BInding Factor
Ford et al. (2), using a biological assay to evaluate the 1L2 synthesis of T lymphocytes in Hodgkin's disease patients, found their values lower than in normal subjects. These results are encouraging, but that method is complex and not feasible in many laboratories.
Recently, we used a commercial immunoenzymatic assay for 1L2 (Intertest 2 Human Interleukin-2 ELISA; Genzyme, Boston, MA 02111) to compare the 1L2 concentration in serum from normal subjects and patients with Hodgkin's disease. The test is based on use of a purified mouse monoclonal antibody as first antibody, rabbit polyclonal antibody against 1L2 as the second. The standards consist of recombinant 1L2 (rIL2) at concentrations from 0.05 tO 500 kilo-int. unitsfL.
We tested the 1L2 content in serum from 13 normal subjects and 46 patients with Hodgkin's disease and found values ranging from 0 to 5000 kilo-mt. units/L, with no significant differences between the two groups. Nor was 1L2 correlated with the disease activity indices, immunoglobulin concentrations, or lymphocyte count. In eight subjects, four normals and four patients, we found very low concentrations of 1L2. Furthermore, when we added a standard solution of,iL2 to these sera, even this 1L2 disappeared.
To characterize this phenomenon, we incubated rIL2, 500 kilo-mt. units/L, for 1 h with buffer or serum at room temperature, then performed all the assay steps according to the manufacturer's instructions.
As shown in Figure 1 , 1L2 was no longer detectable in the sera. This phenomenon was Ag. 1. Resultsof recombinant 1L2 assay Dof tedline: 500 kilo-mt units/I.,lL2 standard diluted with buffer(PBS pH 7.4).
SoiWine:5O0 kilo-mt.units/L,1L2standarddilutedwith serum from eight subjects with low 11.2content not due to serum storage: similar results were obtained with fresh samples and with samples stored at -20 #{176}C.
This phenomenon, wellknown as the "serum effect," has been described for other proteins (3, 4) and is of particular interest in the case of 1L2, because of the biological role of this analyte. The serum effect might be attributable to the presence of increased 1L2 receptors in serum of patients with lymphoproliferative disorders (5, 6), but this would not account for the serum effect observed in healthy controls.
We plan to characterize the protein responsible for 1L2 "quenching" and to evaluate whether its presence is also correlated with the disappearance of biological activity.
